Download PDF
Klin Padiatr 2008; 220(6): 342-347
DOI: 10.1055/s-0028-1086031
Review Article

© Georg Thieme Verlag KG Stuttgart · New York

TNFα-blocking Agents or Conventional Immunosuppressive Drugs in the Therapy of Children with Uveitis? – An Evidence Based Approach

TNFα-blockierende Substanzen oder konventionelle Immunsuppressiva für die Behandlung von Kindern mit Uveitis? – Eine evidenzbasierte AnalyseS. Winterhalter 1 , T. Niehues 2
  • 1Department of Ophthalmology, University Hospital Düsseldorf, Germany
  • 2Center for Child and Adolescent Health, HELIOS Hospital Krefeld, Germany
Further Information

Publication History

Publication Date:
23 October 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Treatment of childhood uveitis associated with juvenile idiopathic arthritis (JIA) is a challenge for both, ophthalmologists and pediatricians. In this study, we use the tools of evidence based medicine (EBM) to analyse studies concerning disease-modifying antirheumatic drugs (DMARD)/ immunosuppressive drugs and tumor necrosis factor alpha (TNFα) blocking agents. Most experience among DMARD's/ immunosuppressive drugs has been obtained with methotrexate (MTX) in juvenile idiopathic arthritis. However, controlled studies in uveitis are still missing, so that treatment with MTX and all other immunosuppressive drugs (ciclosporine A, azathioprine, mycophenolate mofetil) only reaches an evidence level III (expert opinion, clinical experience or descriptive study). Studies on TNFα-blocking agents reach an evidence level II–III, depending on the substance. In future, MTX will have to be examined in comparison to the new biological substance classes (e.g., tumor necrosis factor-α-blockers) for the treatment of uveitis in juvenile idiopathic arthritis. Controlled studies which have led to the approval of drugs for JIA are needed for uveitis in order to have the most effective and safe therapy for children with uveitis, who do not respond to conventional therapy with local and systemic steroids.

Zusammenfassung

Die Behandlung der JIA-assoziierten Uveitis im Kindes-und Jugendalter (JIA - Juvenile Idiopathische Arthritis) stellt eine Herausforderung sowohl für Augenärzte als auch für Kinderärzte dar. Anhand der Methoden der evidenzbasierten Medizin (EBM) haben wir in dieser Analyse Studien über DMARDs, Immunsuppressiva und Tumor-Nekrose-Faktor-α-blockierenden Substanzen untersucht. Bei der Behandlung der JIA besteht die meiste Erfahrung unter den DMARDs und Immunsuppressiva mit dem Medikament Methotrexat (MTX). Bei der Behandlung der Uveitis fehlen kontrollierte Studien, so dass der Evidenzgrad für die Behandlung mit Methotrexat und anderen Immunsuppressiva (CSA, Azathioprin und MMF) nur den Evidenzgrad III (Expertenmeinung) erreicht. Die Studien bei der Uveitis über TNF-blockierende Substanzen erreichen einen Evidenzgrad II – III, abhängig von der Substanz. In Zukunft wird zur Beurteilung der Effektivität unbedingt notwendig sein, MTX gegen die neuen Biologica zu testen. Kontrollierte Studien, die bei der JIA zur Zulassung der Medikamente geführt haben, sind auch für die Uveitis zu fordern, damit Kindern und Jugendlichen mit einer Uveitis eine effektive und sichere Therapie angeboten werden kann, wenn die konventionelle Therapie und lokal wie systemisch applizierte Steroide versagen.

Key words

uveitis - juvenile idiopathic arthritis - immunosuppression - methotrexate - TNFα-blocking agents - etanercept - infliximab - adalimumab - evidence based medicine

Schlüsselwörter

Uveitis - juvenile idiopathische Arthritis - Immunsuppression - Methotrexat - TNFα-Inhibitoren - Etanercept - Infliximab - Adalimumab - evidence based medicine

References

  • 1 Becker MD, Smith JR, Max R. et al . Management of sight-threating uveitis: new therapeutic options.  Drugs. 2005;  65 497-519
    CrossrefPubMedSearch in Google Scholar
  • 2 Beritez-Del-Castillo JM, Carcia-Sanchez J, Iradier T. et al . Sulfasalzine in the prevention of anterior uveitis associated with ankylosing spondylitis.  Eye. 2000;  14 ((Pt3A)) 340-343
    PubMedSearch in Google Scholar
  • 3 Biester S, Deuter C, Michels H. et al . Adalimumab in the therapy of uveitis in childhood.  Br J Ophthalmol. 2007;  91 319-324
    CrossrefPubMedSearch in Google Scholar
  • 4 Boer J de, Wulffraat N, Rothova A. Visual loss in uveitis in childhood.  Br J Ophthalmol. 2003;  87 879-884
    CrossrefPubMedSearch in Google Scholar
  • 5 Doycheva DG, Deuter C, Stuebiger N. et al . Mycophenolate mofetil in the treatment of uveitis in children.  Br J Ophthalmol. 2007;  91 180-184
    CrossrefPubMedSearch in Google Scholar
  • 6 Edelsten C, Reddy MA, Stanford MR. et al . Visual loss associated with pediatric uveitis in english primary and referral centers.  Am J Ophthalmol. 2003;  135 676-680
    CrossrefPubMedSearch in Google Scholar
  • 7 Feldmann W. Evidence-based Pediatrics. 1 ed. Hamilton: B. Decker 2000
  • 8 Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis.  J Rheumatol. 2005;  32 362-365
    PubMedSearch in Google Scholar
  • 9 Foeldvari I, Nielsen S, Kümmerle-Deschner J. Tumor necrosis factor-alpha blocker in the treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.  J Rheumatol. 2007;  634 1146-1150
    PubMedSearch in Google Scholar
  • 10 Galor A, Jabs DA, Leder HA. et al . Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.  Ophthalmol. 2008;  , Epub ahead of print
    PubMedSearch in Google Scholar
  • 11 Gerloni V, Cimaz R, Gattinara M. et al . Efficacy and safety profile of Cyclosprine A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study.  Rheumatology. 2001;  40 907-913
    CrossrefPubMedSearch in Google Scholar
  • 12 Giannini EH, Brewer EJ, Kuzmina N. et al . Result of the USA – UDSSR double-blind, placebo-controlled trial.  N Engl J Med. 1992;  326 1043-1049
    PubMedSearch in Google Scholar
  • 13 Guignard S, Gossec L, Salliot C. et al . Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospctive study.  Ann Rheum Dis. 2006;  65 1631-1634
    CrossrefPubMedSearch in Google Scholar
  • 14 Heiligenhaus A, Mingels A, Heinz C. et al . Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti inflammatory medication.  Eur J Ophthalmol. 2007;  17 743-748
    PubMedSearch in Google Scholar
  • 15 Heiligenhaus A, Horneff G, Greiner K. et al . Inhibitors of tumor necrois factor alpha for the treatment of arthritis and uveitis in childhood.  Klin Monatsbl Augenheilkd. 2007;  224 526-531
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Hemady RK, Baer JC, Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis.  Int Ophthalmol Clin. 1992;  32 241-252
    CrossrefPubMedSearch in Google Scholar
  • 17 Kaiplainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondylarthropathy associated with tumor necrosis factor inhibitors.  Ann Rheum Dis. 2003;  62 88-89
    CrossrefPubMedSearch in Google Scholar
  • 18 Kilmartin DJ, Forrester JV, Dick AD. Cyclosporine A therapy in refracotry noninfectious childhood uveitis.  Br J Ophthalmol. 1998;  82 737-742
    CrossrefPubMedSearch in Google Scholar
  • 19 Kotaniemi K. Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporine A and methotrexate.  Clin Exp Rheumatol. 1998;  16 549-571
    PubMedSearch in Google Scholar
  • 20 Kvien TK, Hoyerall HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study.  J Rheumatol. 1986;  13 118-123
    PubMedSearch in Google Scholar
  • 21 Lau CH, Comer M, Lightman S. Long-term efficacy of mycophonolate mofetil in the control of severe intaocular inflammation.  Clin Experiment Ophthalmol. 2003;  31 487-491
    CrossrefPubMedSearch in Google Scholar
  • 22 Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate.  Am J Ophthalmol. 1969;  67 383-387
    PubMedSearch in Google Scholar
  • 23 Lovell DJ, Giannini EH, Reiff A. et al . Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheujmatoid arthritis: interim results from an ongoing multicenter, open-labe, extended-treatment trial.  Arthritis Rheum. 2003;  48 218-226
    CrossrefPubMedSearch in Google Scholar
  • 24 Lovell DJ, Reiff A, Jones OY. et al . Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.  Arthritis Rheum. 2006;  54 1987-1994
    CrossrefPubMedSearch in Google Scholar
  • 25 Lovell DJ, Reiff A, Ilowite NT. et al . Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.  Arthritis Rheum. 2008;  58 1496-1504
    CrossrefPubMedSearch in Google Scholar
  • 26 Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J. et al . Sulfasalzine reduces the number of flares of acute anterior uveitis over a one-year period.  J Rheumatol. 2003;  30 1277-1279
    PubMedSearch in Google Scholar
  • 27 Rajaraman RT, Kumura Y, Li S. et al . Retrospective case review of pediatric patients with uveitis treated with infliximab.  Ophthalmology. 2006;  113 308-314
    CrossrefPubMedSearch in Google Scholar
  • 28 Reddy AR, Backhouse OC. Does etanercept induce uveitis?.  Br J Ophthalmol. 2005;  89 925
    CrossrefPubMedSearch in Google Scholar
  • 29 Reiff A, Takei S, Sadeghi S. et al . Etanercept therapy in children with treatment-resistant uveitis.  Arthritis Rheum. 2001;  44 1411-1415
    CrossrefPubMedSearch in Google Scholar
  • 30 Richards JC, Tay-Kearney ML, Murray K. et al . Infliximab for juvenile idiopathic arthritis-associated uveitis.  Clin Exp Ophthalmol. 2005;  33 461-468
    CrossrefPubMedSearch in Google Scholar
  • 31 Ruperto N, Murray KJ, Gerloni V. et al . A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.  Arthritis Rheum. 2004;  50 2191-2201
    CrossrefPubMedSearch in Google Scholar
  • 32 Ruperto N, Lovell DJ, Cuttica R. et al . A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.  Arthritis Rheum. 2007;  56 3096-3106
    CrossrefPubMedSearch in Google Scholar
  • 33 Sackett DL, Rosenberg WM, Gray JA. Evidence based medicine: what it is and what it isn’t.  BMJ. 1996;  13 71-72
    PubMedSearch in Google Scholar
  • 34 Samson CM, Waheed N, Baltatzis S. et al . Methotrexate therapy for chronic noninfectious uveits: analyses of a case series of 160 patients.  Ophthalmolgy. 2001;  108 1134-1139
    CrossrefPubMedSearch in Google Scholar
  • 35 Saurenmann RK, Levin AV, Rose JB. et al . Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis.  Rheumatology. 2006;  45 982-989
    CrossrefPubMedSearch in Google Scholar
  • 36 Schlote T, Danecker G, Thiel HF. et al . Cyclosporine A in therapy of chronic uveitis in childhood.  Ophthalmologe. 1996;  93 745-748
    CrossrefPubMedSearch in Google Scholar
  • 37 Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis.  Rheumatology. 2005;  44 1008-1011
    CrossrefPubMedSearch in Google Scholar
  • 38 Shetty AK, Zganjar BE, Ellis Jr GS. et al . Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis.  J Pediatr Ophthalmol Strabismus. 1999;  36 125-129
    PubMedSearch in Google Scholar
  • 39 Smith JR, Levinson RD, Holland GN. et al . Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic diesease.  Arthritis Rheum. 2001;  45 252-257
    CrossrefPubMedSearch in Google Scholar
  • 40 Smith JA, Thompson DJ, Whitcup SM. et al . A randomized, placebo controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.  Arthritis Rheum. 2005;  53 18-23
    CrossrefPubMedSearch in Google Scholar
  • 41 SUN-Working Study Group . Perspectives-standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.  J Ophthalmol. 2005;  140 509-516
    CrossrefPubMedSearch in Google Scholar
  • 42 Tappeiner C, Roesel M, Heinz C. et al . Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis.  Eye. 2008;  , Epub ahead of print
    PubMedSearch in Google Scholar
  • 43 Tynjälä P, Lindahl P, Honkanen V. et al . Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.  Ann Rheum Dis. 2007;  66 548-550
    CrossrefPubMedSearch in Google Scholar
  • 44 Rossum MA van, Fiselier TJ, Franssen MJ. Dutch Juvenile Chronic Arthritis Study Group . Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study.  Arthritis Rheum. 1998;  41 808-816
    CrossrefPubMedSearch in Google Scholar
  • 45 Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis.  J Pediatr. 1998;  133 266-268
    PubMedSearch in Google Scholar
  • 46 Wells G, Haguenauer D, Shea B. et al . Cyclosporine for rheumatoid arthritis.  Cochrane Database Syst Rev. 2006;  2 CD001083
    PubMedSearch in Google Scholar
  • 47 Woo P, Southwood TR, Prieur AM. et al . Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.  Arthritis Rheum. 2000;  j43 1849-1857
    CrossrefPubMedSearch in Google Scholar

Correspondence

Dr. Sibylle Winterhalter

Department of Ophthalmology

University Hospital Düsseldorf Moorenstr. 5

40225 Düsseldorf

Germany

Phone: +49/211/81 173 22

Fax: +49/211/81 195 57

Email: billewin@gmx.de